AdAlta Limited (ASX:1AD)
Australia · Delayed Price · Currency is AUD | Market Cap | 11.95M +106.5% |
| Revenue (ttm) | 608.07K -37.5% |
| Net Income | -4.36M |
| EPS | -0.00 |
| Shares Out | 2.66B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,200 |
| Open | 0.0040 |
| Previous Close | 0.0040 |
| Day's Range | 0.0040 - 0.0040 |
| 52-Week Range | 0.0020 - 0.0080 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 3, 2026 |
About AdAlta
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe Univers... [Read more]
Financial Performance
In fiscal year 2025, AdAlta's revenue was 677,010, a decrease of -61.04% compared to the previous year's 1.74 million. Losses were -4.50 million, -16.33% less than in 2024.
Financial StatementsNews
AdAlta Transcript: Investor update
BZDS1901, a CAR T-cell therapy for mesothelioma, has shown unprecedented complete response rates in advanced patients and is positioned for global expansion via an East to West strategy. Manufacturing and clinical milestones are progressing, with a phase I Australian trial targeted for late 2027.
AdAlta Slides: Investor update
AdAlta has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
AdAlta Earnings release: Q3 2026
AdAlta released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
AdAlta Quarterly report: H1 2026
AdAlta has published its H1 2026 quarterly earnings report on February 19, 2026.
AdAlta Slides: Investor presentation
AdAlta has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.
AdAlta Transcript: Status update
A new CAR-T cell therapy for mesothelioma, BZDS1901, has been in-licensed and will undergo Phase I trials in Australia, targeting a $4.2 billion market. Early clinical data show strong efficacy, and the program is structured for capital efficiency and rapid value creation.
AdAlta Slides: Status update
AdAlta has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
AdAlta Slides: FY 2025
AdAlta has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 25, 2025.
AdAlta Earnings release: Q1 2026
AdAlta released its Q1 2026 earnings on October 27, 2025, summarizing the period's financial results.
AdAlta Annual report: H2 2025
AdAlta has published its H2 2025 annual report on August 27, 2025.
AdAlta Slides: Investor Presentation
AdAlta has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2025.
AdAlta Earnings release: Q4 2025
AdAlta released its Q4 2025 earnings on July 22, 2025, summarizing the period's financial results.